PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar EclecticRecluse (77.78) Submitted: 5/25/2011 10:01:35 AM : Outperform Start Price: $5.86 PDLI Score: +10.30

Good Forward Earnings Estimate

Report this Post Reply

Featured Broker Partners


Advertisement